Axonics, Inc. (AXNX)

66.87 +0.30 (+0.45%) At close: 04:00PM EDT

Axonics, Inc.

26 Technology Drive
Irvine, CA 92618
United States
949 396 6322
https://www.axonics.com

Sector(s): Healthcare
Industry: Medical Devices
Full-time employees: 797

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Raymond W. Cohen	CEO & Director	1.71M	N/A	1959
Mr. Rinda K. Sama	Chief Operating Officer	902.83k	1.78M	1979
Dr. John Woock Ph.D.	Executive VP, Chief Marketing & Strategy Officer	902.83k	1.06M	1983
Mr. Alfred J. Ford Jr.	Chief Commercial Officer	902.96k	N/A	1971
Ms. Kari Keese	Chief Financial Officer	N/A	N/A	N/A
Mr. Guangqiang Jiang Ph.D.	Chief Technology Officer	N/A	N/A	1974
Mr. Neil Bhalodkar	Vice President of Investor Relations	N/A	N/A	N/A
Mr. Aaron Pettit	General Counsel & Chief Compliance Officer	N/A	N/A	N/A
Mr. Michael V. Williamson Esq., J.D.	Senior VP, General & IP Counsel	N/A	N/A	1972
Dr. Karen L. Noblett M.A.S., M.D.	Chief Medical Officer	651.4k	897.47k	1963

Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Axonics, Inc., a medical technology company, engages in the development and commercialization of novel products for the treatment of bladder and bowel dysfunction. Its sacral neuromodulation (SNM) systems are used to treat patients with overactive bladder (OAB), including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence (FI) and non-obstructive urinary retention (UR); and rechargeable (R20) and recharge-free (F15) implantable SNM systems that delivers mild electrical pulses to the targeted sacral nerve to restore normal communication to and from the brain to reduce the symptoms of OAB, UR, and FI. The company also offers Bulkamid, a urethral bulking agent to treat female stress urinary incontinence. It sells its products through a direct sales force and distributors in the United States, the United Kingdom, Germany, the Netherlands, Nordic countries, and internationally. The company was formerly known as Axonics Modulation Technologies, Inc. and changed its name to Axonics, Inc. in March 2021. Axonics, Inc. was incorporated in 2012 and is based in Irvine, California.

Corporate governance

Axonics, Inc.’s ISS governance QualityScore as of 29 April 2024 is 4. The pillar scores are Audit: 10; Board: 2; Shareholder rights: 4; Compensation: 2.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.